Low dose lamotrigine — Competitive Intelligence Brief

Low dose lamotrigine (Low dose lamotrigine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Mood stabilizer. Area: Neurology / Psychiatry.

marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release modulation Neurology / Psychiatry Small molecule

Target snapshot

Low dose lamotrigine (Low dose lamotrigine) — Mario Negri Institute for Pharmacological Research. Low-dose lamotrigine reduces neuronal excitability by blocking voltage-gated sodium channels and inhibiting glutamate release.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low dose lamotrigine TARGET	Low dose lamotrigine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release modulation
Paroxetine+Lamotrigine	Paroxetine+Lamotrigine	Ministry of Health & Welfare, Korea	marketed	SSRI + anticonvulsant mood stabilizer combination	Serotonin transporter (SERT); voltage-gated sodium channels; glutamate release modulation
Lamictal TM	Lamictal TM	Central Mental Clinic for Outpatients of Baku City	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine tablet	Lamotrigine tablet	Dhaka Medical College	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
valproate microgranules	valproate microgranules	Sanofi	marketed	Anticonvulsant / Mood stabilizer	Histone deacetylase; GABA metabolism
Lamotrigine generic "B"	Lamotrigine generic "B"	University of Cincinnati	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Brand lamotrigine	Brand lamotrigine	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Mood stabilizer class)

1. University of Maryland, Baltimore · 4 drugs in this class
2. Sanofi · 2 drugs in this class
3. University of Cincinnati · 2 drugs in this class
4. Mario Negri Institute for Pharmacological Research · 1 drug in this class
5. Central Mental Clinic for Outpatients of Baku City · 1 drug in this class
6. The University of Texas Health Science Center at San Antonio · 1 drug in this class
7. University Hospitals Cleveland Medical Center · 1 drug in this class
8. Dhaka Medical College · 1 drug in this class
9. Korea Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class